<DOC>
	<DOCNO>NCT00724282</DOCNO>
	<brief_summary>Available data suggest obtain adequate sleep associate well ability body use carbohydrates source energy low risk develop diabetes . The sleeping pill , Eszopiclone ( Lunesta ) , approve Food Drug Administration treatment people complain trouble fall stay asleep . This study examine hypothesis use Eszopiclone ( Lunesta ) improve sleep people insomnia may also improve use sugar body .</brief_summary>
	<brief_title>Treatment Insomnia Glucose Metabolism</brief_title>
	<detailed_description>Study participant complete set oral intravenous glucose ( sugar ) tolerance test , perform two separate occasion random order : week treatment Eszopiclone ( Lunesta ) week receive placebo .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>age 35 64 must longstanding trouble fall stay asleep BMI 22 34 kg/m2 sleep apnea sleep disorder insomnia diagnosis diabetes require treatment pill insulin smoke night shift work presence medical condition disrupt sleep woman : irregular menstrual period pregnancy use medications/compounds disrupt sleep</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>sleep</keyword>
	<keyword>eszopiclone</keyword>
	<keyword>insulin secretion</keyword>
	<keyword>insulin action</keyword>
	<keyword>glucose tolerance</keyword>
</DOC>